国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2012年
11期
801-803
,共3页
支气管哮喘%慢性阻塞性肺疾病%噻托溴铵
支氣管哮喘%慢性阻塞性肺疾病%噻託溴銨
지기관효천%만성조새성폐질병%새탁추안
Bronchial asthma%Chronic obstructive pulmonary disease%Tiotropium
目的 探讨噻托溴铵(思力华)联合沙美特罗替卡松(舒利迭)吸入治疗中重度支气管哮喘(简称哮喘)合并慢性阻塞性肺疾病(COPD)的临床疗效.方法 将126例中重度哮喘合并COPD患者随机分人对照组与观察组,对照组患者接受沙美特罗替卡松吸入,给予观察组患者噻托溴铵联合沙美特罗替卡松吸入.比较两组患者治疗前及治疗后1年肺功能的改变,急性发作次数、住院次数、急性发作的间隔时间以及生活质量.结果 治疗后观察组第1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEVt％pred)和用力肺活量(FVC)显著优于对照组(P＜0.05)；随访1年,观察组急性发作次数及住院次数显著少于对照组(P＜0.05),急性发作的间隔时间差异无统计学意义(P＞0.05)；观察组生活质量SGRQ评分各维度及总分显著低于对照组,差异有统计学意义(P＜0.05).结论 噻托溴铵联合沙美特罗替卡松吸入可显著改善中重度哮喘合并CO PD患者肺功能,提高临床疗效及患者生活质量.
目的 探討噻託溴銨(思力華)聯閤沙美特囉替卡鬆(舒利迭)吸入治療中重度支氣管哮喘(簡稱哮喘)閤併慢性阻塞性肺疾病(COPD)的臨床療效.方法 將126例中重度哮喘閤併COPD患者隨機分人對照組與觀察組,對照組患者接受沙美特囉替卡鬆吸入,給予觀察組患者噻託溴銨聯閤沙美特囉替卡鬆吸入.比較兩組患者治療前及治療後1年肺功能的改變,急性髮作次數、住院次數、急性髮作的間隔時間以及生活質量.結果 治療後觀察組第1秒用力呼氣容積(FEV1)、FEV1佔預計值百分比(FEVt％pred)和用力肺活量(FVC)顯著優于對照組(P＜0.05)；隨訪1年,觀察組急性髮作次數及住院次數顯著少于對照組(P＜0.05),急性髮作的間隔時間差異無統計學意義(P＞0.05)；觀察組生活質量SGRQ評分各維度及總分顯著低于對照組,差異有統計學意義(P＜0.05).結論 噻託溴銨聯閤沙美特囉替卡鬆吸入可顯著改善中重度哮喘閤併CO PD患者肺功能,提高臨床療效及患者生活質量.
목적 탐토새탁추안(사력화)연합사미특라체잡송(서리질)흡입치료중중도지기관효천(간칭효천)합병만성조새성폐질병(COPD)적림상료효.방법 장126례중중도효천합병COPD환자수궤분인대조조여관찰조,대조조환자접수사미특라체잡송흡입,급여관찰조환자새탁추안연합사미특라체잡송흡입.비교량조환자치료전급치료후1년폐공능적개변,급성발작차수、주원차수、급성발작적간격시간이급생활질량.결과 치료후관찰조제1초용력호기용적(FEV1)、FEV1점예계치백분비(FEVt％pred)화용력폐활량(FVC)현저우우대조조(P＜0.05)；수방1년,관찰조급성발작차수급주원차수현저소우대조조(P＜0.05),급성발작적간격시간차이무통계학의의(P＞0.05)；관찰조생활질량SGRQ평분각유도급총분현저저우대조조,차이유통계학의의(P＜0.05).결론 새탁추안연합사미특라체잡송흡입가현저개선중중도효천합병CO PD환자폐공능,제고림상료효급환자생활질량.
Objective To explore the clinical effect of tiotropium combined with salmeterol fluticasone propionate in medium and heavy bronchial asthma (asthma) merger chronic obstructive pulmonary disease (COPD).Methods 126 cases with medium and heavy asthma merger COPD were randomly divided into control group and experience group.Control group were given salmeterol flutieasone propionate inhalation,and experience group were treated with tiotropium combined with salmeterol fluticasone propionate.The change of lung function,time of acute attack,frequency ofhospitalization and acute onset of the next interval before and 1 year after treatment were compared between two groups.Results FEV1,FEV1 ％
pred and FVC after treatment in experience group were superior to that in control group (P＜0.05).In the follow-up of 1 year,time of acute attack and frequency of hospitalization in experience group were much less than that in control group (P＜0.05),and there was no significant different of acute onset of the next interval between two groups (P＞0.05).Each dimension and total score of SGRQ after intervention in experience group were much lower than that in control group (P＜0.05).Conclusions Tiotropium combined with salmeterol fluticasone propionate for medium and heavy asthma merger COPD can greatly improve the lung function,clinical effect and patients'life quantity.
